RankAlpha logo
Back to Rankings

UNCY

Unicycive TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
+
Peers tracked
11
U.S. public peers
Grade Position
Below peers
vs peer average
UNCY vs peer average
43/100
UNCY vs. peer average (D vs. D)
Grade spread
A 1 · C 4 · D 4 · F 2
Graded peers loaded
Coverage
11 graded
100% of tracked

Peer overview

ARDX is the first available peer comparator.

Ardelyx is a direct operating comparator because Xphozah is explicitly listed by Unicycive as a competing phosphate-lowering therapy, making it relevant for formulary, adoption, and dialysis-channel execution benchmarks.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerARDXArdelyx
UNCY
Unicycive Therapeutics
ARDX
Ardelyx
Grade
D
C
Momentum
3
6
Value
41
41
Sentiment
84
99
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Mixed
Open Side-by-Side ComparisonCompare all

Grade position vs ARDX

UNCY / ARDX
Grade Position
Below peers
UNCY vs. peer average (D vs. D)
43/100
Momentum
3
ARDX
Value
41
UNCY
Sentiment
84
ARDX

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs UNCY
1
ARDX
ARDX
C
60/100
-1
2
AKBA
AKBA
D
40/100
Even
3
FMS
FMS
D
40/100
Even
4
MIST
Milestone Pharmaceuticals Inc Common
D
40/100
Even
5
RCEL
AVITA Medical Inc Common
C
60/100
-1
ARDX is the first peer returned for this comparison set.